Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia

Content Provider	Scilit
Author	Billett, Al Kornmehl, E. Tarbell, Nj Weinstein, H. J. Gelber, Rd Ritz, J. Sallan, Se
Copyright Year	1993
Description	Fifty-one children with acute lymphoblastic leukemia (ALL) in second or subsequent remission after a first remission of at least 24 months underwent purged, autologous bone marrow transplantation (ABMT). Bone marrow was harvested in remission and purged in vitro with monoclonal antibodies specific for leukemia-associated antigens. Ablative chemotherapy included cytarabine, teniposide, and cyclophosphamide followed by total body irradiation. Of the 51 patients treated between November 1980 and June 1991, 5 died of treatment-related complications, 18 relapsed, 1 died of a second tumor at 6.7 years, and 27 remained in continuous complete remission for a median of 39 months (range, 9+ to 124+). Event-free survival (EFS) (+/- SE) at 3 years after ABMT was 53% +/- 7%. Leukemia-free survival (LFS) was 58% +/- 8%. In multivariate analysis, the most significant predictors of EFS were duration of longest pre-ABMT remission and remission duration immediately before ABMT. For LFS, the most significant predictors were cell dose per kilogram of marrow reinfused and duration of longest pre-ABMT remission. We conclude that ABMT for this population is an effective therapy available to the majority of children with relapsed ALL.
Related Links	https://ashpublications.org/blood/article-pdf/81/6/1651/610135/1651.pdf
Ending Page	1657
Page Count	7
Starting Page	1651
DOI	10.1182/blood.v81.6.1651.1651
Journal	Blood
Issue Number	6
Volume Number	81
Language	English
Publisher	American Society of Hematology
Publisher Date	1993-03-15
Access Restriction	Open
Subject Keyword	Hematology Children Multivariate Analysis Survival Antibodies Bone Marrow Antigens Leukemia Remission Abmt Journal: Blood (Vol- 89, Issue- 6)
Content Type	Text
Resource Type	Article